Versartis, Inc. (NASDAQ:VSAR) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity set a $28.00 price target on Versartis and gave the company a “buy” rating in a research report on Sunday, May 28th. Cantor Fitzgerald began coverage on Versartis in a research report on Thursday, May 4th. They issued an “overweight” rating and a $34.00 target price for the company. BidaskClub downgraded Versartis from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Cowen and Company reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Versartis in a research report on Wednesday, August 23rd. Finally, Zacks Investment Research raised Versartis from a “sell” rating to a “hold” rating in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $27.88.

Versartis (NASDAQ VSAR) traded up 2.11% during midday trading on Friday, reaching $19.40. The company’s stock had a trading volume of 433,207 shares. The company’s market capitalization is $690.21 million. The company has a 50 day moving average of $18.06 and a 200-day moving average of $18.40. Versartis has a 1-year low of $9.05 and a 1-year high of $24.00.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.20. Equities research analysts anticipate that Versartis will post ($3.49) earnings per share for the current fiscal year.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/01/versartis-inc-vsar-upgraded-to-hold-by-valuengine.html.

Several large investors have recently modified their holdings of VSAR. American International Group Inc. increased its stake in shares of Versartis by 20.7% in the first quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 3,250 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Versartis during the first quarter valued at $563,000. Alambic Investment Management L.P. boosted its position in Versartis by 148.7% in the first quarter. Alambic Investment Management L.P. now owns 30,378 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 18,165 shares during the period. Oxford Asset Management boosted its position in Versartis by 240.9% in the first quarter. Oxford Asset Management now owns 124,744 shares of the biopharmaceutical company’s stock valued at $2,663,000 after buying an additional 88,151 shares during the period. Finally, Trexquant Investment LP acquired a new position in Versartis during the first quarter valued at approximately $600,000. 78.77% of the stock is owned by institutional investors.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Stock Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related stocks with our FREE daily email newsletter.